IGF-1 DES

IGF-1 DES lacks the first three amino acids of native insulin-like growth factor-1. This truncation reduces binding to IGF-binding proteins and increases potency in laboratory systems. It circulates as a research chemical and performance-enhancing product, not an approved medicine. It is distinct from IGF-1 LR3 and from full-length mecasermin.

Supporting references: carrier proteins.

The molecule activates IGF-1 receptors involved in protein synthesis and tissue growth. Weaker carrier-protein binding provides a rationale for greater local activity than native IGF-1 in experimental systems. Rodent findings include improved nitrogen balance and reduced muscle-protein breakdown; cell culture uses it as a potent growth stimulus. Laboratory potency is not a measured human performance outcome.

An indexed animal experiment reported improved nitrogen balance and reduced protein breakdown, and cell-growth assays demonstrate strong reagent activity. There are no human clinical trials supporting the marketed muscle/performance use in this account. Human benefit, a validated regimen and clinical safety cannot be inferred from those experimental findings.

Supporting references: study; DOI: 10.3389/fendo.2026.1822475.

IGF-1 DES has no FDA approval or approved compounding status in the reported context. The full-length IGF-1 medicine mecasermin has a specific rare-growth-disorder indication that does not transfer to DES. WADA prohibits IGF-1 and its analogs at all times, independently of whether vendors label them research products.